After Going to Market

Ruth Faden and her colleagues, who were part of an Institute of Medicine committee, examine the ethics of postmarketing research in a New England Journal of Medicine essay. Back in 2008, the US Food and Drug Administration told GlaxoSmithKline to look into whether its drug Avandia (rosiglitazone) was associated with a higher risk of heart attack and death as compared to placebo or other, unrelated drug therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.